F
Filip K. Knop
Researcher at University of Copenhagen
Publications - 523
Citations - 17834
Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.
Papers
More filters
Journal Article
The benefits of diagnostic imaging in general practice
Filip K. Knop,Jens Aage Stauning +1 more
TL;DR: It is concluded that patients in a single-doctor general practice are given radiographic examinations of the thorax and hips relatively infrequently, while radiographs of theThoracic and lumbar spine and abdominal ultrasound scans are done more frequently and more often result in clinical intervention.
Journal ArticleDOI
Long-acting amylin analogues for the management of obesity
TL;DR: Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide.
Journal ArticleDOI
Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy Controls.
TL;DR: The plasma proANP response to oral glucose and 3 isocaloric and isovolemic liquid meals in patients with type 2 diabetes and matched controls is examined to suggest that the cardiac natriuretic peptides are involved in metabolic regulation.
Journal ArticleDOI
Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes
TL;DR: The authors provide an update on the development and clinical potential of colesevelam as a glucose-lowering drug in T2D and outline the pharmacokinetics, pharmacodynamics, and the clinical efficacy and safety data from the studies carried out to obtain market authorization.
Posted ContentDOI
Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
Angela Kim,Jakob G. Knudsen,Jakob G. Knudsen,Joseph C. Madara,Anna Benrick,Thomas Hill,Lina Abdul Kadir,Joely A. Kellard,Lisa Mellander,Caroline Miranda,Haopeng Lin,Timothy Y. James,Kinga Suba,Aliya F. Spigelman,Yanling Wu,Patrick E. MacDonald,Ingrid Wernstedt Asterholm,Tore Magnussen,Mikkel Christensen,Mikkel Christensen,Tina Visboll,Tina Visboll,Tina Visboll,Victoria Salem,Filip K. Knop,Patrik Rorsman,Bradford B. Lowell,Linford J.B. Briant +27 more
TL;DR: In this paper, it was shown that arginine-vasopressin (AVP), secreted from the posterior pituitary, stimulates glucagon secretion and mediates the stimulatory effects of hypoglycemia produced by exogenous insulin and 2-deoxy-D-glucose on glucagon release.